(Q46506804)

22 December 2017

title

Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation (English)

1 reference

22 December 2017

1 reference

Wengang Cao

1

1 reference

22 December 2017

Kathleen T Shiverick

2

1 reference

22 December 2017

Kazunori Namiki

3

1 reference

22 December 2017

Yoshihisa Sakai

4

1 reference

22 December 2017

Stacy Porvasnik

5

1 reference

22 December 2017

Cydney Urbanek

6

1 reference

22 December 2017

Charles J Rosser

7

1 reference

22 December 2017

publication date

2 July 2008

1 reference

22 December 2017

published in

World Journal of Urology

1 reference

22 December 2017

volume

26

1 reference

22 December 2017

issue

5

1 reference

22 December 2017

page(s)

509-516

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1007/s00345-008-0289-5

exact match

0 references

cites work

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00345-008-0289-5

Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity

21 January 2018

1 reference

12 December 2020

Prostate cancer incidence and mortality rates among white and black men.

1 reference

12 December 2020

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x

1 reference

12 December 2020

Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy--a dose-escalation study

1 reference

12 December 2020

1 reference

12 December 2020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

12 December 2020

Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity

1 reference

12 December 2020

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

1 reference

12 December 2020

Taxol suppresses dynamics of individual microtubules in living human tumor cells

1 reference

12 December 2020

Prostate cancer. Radiation therapy for localized disease

1 reference

12 December 2020

Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma

1 reference

12 December 2020

Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy.

1 reference

12 December 2020

BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

1 reference

12 December 2020

Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone

1 reference

12 December 2020

p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy

1 reference

12 December 2020

The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation

1 reference

12 December 2020

Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor

1 reference

12 December 2020

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

12 December 2020

Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.

1 reference

12 December 2020

Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation

1 reference

12 December 2020

Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts.

1 reference

12 December 2020

PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer

1 reference

12 December 2020

Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins

1 reference

12 December 2020

Docetaxel: a review of its use in metastatic breast cancer

1 reference

12 December 2020

bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer

1 reference

12 December 2020

Complications of definitive radiotherapy for carcinoma of the prostate

1 reference

12 December 2020

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

12 December 2020

Cancer statistics, 2007

1 reference

12 December 2020

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

12 December 2020

10.1007/S00345-008-0289-5

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017